The role of adjuvant immunomodulatory agents for treatment of severe influenza.
The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res. 2018 Jan 08;: Authors: Hui DS, Lee N, Chan PK, Beigel JH Abstract A severe inflammatory immune response with hypercytokinemia occurs in patients hospitalized with severe influenza, such as avian influenza A(H5N1), A(H7N9), and seasonal A(H1N1)pdm09 virus infections. The role of immunomodulatory therapy is unclear as there have been limited published data based on randomized controlled trials (RCTs). Passive immunotherapy such as convalescent plasma and hyperimmune globulin have some studies demonstrating benefit when administered as an adjunctive therapy for severe influenza. Triple combination of oseltamivir, clarithromycin, and naproxen for severe influenza has one study supporting its use, and confirmatory studies would be of great interest. Likewise, confirmatory studies of sirolimus without concomitant corticosteroid therapy should be explored as a research priority. Other agents with potential immunomodulating effects, including non-immune intravenous immunoglobulin, N-acetylcysteine, acute use of statins, macrolides, pamidronate, nitazoxanide, chloroquine, antiC5a antibody, interferons, human mesenchymal stromal cells, mycophenolic acid, peroxisome proliferator-activated receptors agonists, non-steroidal anti-inflammatory agents, mesalazine, herbal medicine, and the role of plasmapheresis and hemoperfusion as rescue therapy have supportive preclinical or...
ConclusionChronic preoperative steroid is not a significant risk factor for surgical site infection following rTKA, but it is independently associated with increased risk of septic shock and prolonged hospital length of stay.
Publication date: Available online 27 January 2020Source: Pharmacology &TherapeuticsAuthor(s): Wei-Jia Kong, Claudio Vernierib, Marco Foiani, Jian-Dong JiangAbstractBerberine (BBR) is a multi-target drug (MTD) that has proven effective in the treatment of metabolism-related chronic diseases (CDs). However, the mode of action (MOA) of BBR remains to be clarified. At a cellular level, the inhibitory effect of BBR on mitochondrial enzymes is probably responsible for many of its biological activities, including the activation of low-density lipoprotein receptor (LDLR), AMP-activated protein kinase (AMPK) and insulin recept...
Publication date: Available online 28 January 2020Source: Journal of EthnopharmacologyAuthor(s): Yu Wang, Yan-Jiao Chen, Cheng Xiang, Guang-Wei Jiang, Yu-Dong Xu, Lei-Miao Yin, Dong-Dong Zhou, Yan-Yan Liu, Yong-Qing YangAbstractEthnopharmacological relevanceStandard therapy for asthma, a highly heterogeneous disease, is primarily based on bronchodilators and immunosuppressive drugs, which confer short-term symptomatic relief but not a cure. It is difficult to discover novel bronchodilators, although potential new targets are emerging. Traditional Chinese Medicine (TCM) formulas have been used to treat asthma for more than ...
ConclusionThe present results suggest that Yinning Tablet ameliorates thyroid hormone-induced liver injury in rats by regulating mitochondria-mediated apoptotic signals. Our findings go insight into the pharmacological basis of the hospitalized preparation for treatment of hyperthyroidism-associated liver injury.Graphical abstract
ConclusionsThese findings suggest that MXYF inhibits autophagy after OGD/R-induced PC12 cell injury through the AMPK-mTOR pathway. Thus, MXYF might have therapeutic potential in treating ischemic stroke.Graphical abstract
Publication date: February 2020Source: JACC: Heart Failure, Volume 8, Issue 2Author(s): Chao Liu, Kunshen Liu
ConclusionsIn this high-risk, low-income cohort, contributions of risk factors to HF varied, particularly by race. To reduce the population burden of HF, interventions tailored for specific race and sex groups may be warranted.Central Illustration
Publication date: February 2020Source: JACC: Heart Failure, Volume 8, Issue 2Author(s): Òscar Miró, Koji Takagi, Pere Llorens, Alexandre Mebazaa
ConclusionsOur results demonstrate that the incidence of GVHD after daratumumab is low and did not result in increased exacerbation of GVHD in patients with prior history of GVHD.